Cooper, RE;
Mason, JP;
Calton, T;
Richardson, J;
Moncrieff, J;
(2021)
Opinion Piece: The case for establishing a minimal medication alternative for psychosis and schizophrenia.
Psychosis
, 13
(3)
pp. 276-285.
10.1080/17522439.2021.1930119.
Preview |
Text
Opinion piece The case for establishing a minimal medication approach.pdf - Other Download (211kB) | Preview |
Abstract
The development of severe mental health conditions is strongly linked to our environments, particularly experiences of trauma and adversity. However treatments for severe mental health conditions are often primarily biomedical, centred around medication. For people diagnosed with schizophrenia or psychosis, this is antipsychotic medication. Although antipsychotics have been found to reduce symptoms and risk of relapse, some patients derive little benefit from these drugs, and they can lead to severe adverse effects. Subsequently, a high proportion of people do not want to take antipsychotics and request an alternative. Yet in the UK and in many countries there are currently no guidelines for stopping antipsychotics or formal treatment alternatives, despite such alternatives being available in some countries. For example, in Norway and Vermont (USA), in response to pressure from service user organisations, governments have mandated the establishment of “minimal medication” services. We examine whether everyone with a psychotic condition needs long-term antipsychotic treatment and evidence for alternative models of care. We recommend that healthcare providers should be encouraged to develop a psychosocial treatment package for people with psychosis or schizophrenia that provides a realistic possibility of minimising antipsychotic exposure.
Type: | Article |
---|---|
Title: | Opinion Piece: The case for establishing a minimal medication alternative for psychosis and schizophrenia |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1080/17522439.2021.1930119 |
Publisher version: | https://doi.org/10.1080/17522439.2021.1930119 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Social Sciences, Science & Technology, Life Sciences & Biomedicine, Psychology, Clinical, Psychiatry, Psychology, Psychosis, schizophrenia, minimal medication, psychosocial treatments, antipsychotic reduction or discontinuation, alternative treatments, ANTIPSYCHOTIC MEDICATION, 1ST-EPISODE PSYCHOSIS, FOLLOW-UP, DISCONTINUATION, PEOPLE, DRUGS, NEUROLEPTICS, METAANALYSIS, MORTALITY, SYMPTOMS |
UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
URI: | https://discovery.ucl.ac.uk/id/eprint/10148335 |
Archive Staff Only
View Item |